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Abstract
PAX5 encodes a master regulator of B-cell development. It fuses to other genes associated with 
acute lymphoblastoid leukemia (ALL). These fusion products are potent dominant-negative (DN) 
inhibitors of wild-type PAX5 resulting in a blockade of B-cell differentiation. Here, we show that 
multimerization of PAX5 DNA-binding domain (DBD) is necessary and sufficient to cause 
extremely stable chromatin binding and DN-activity. ALL-associated PAX5-C20S results from 
fusion of the N-terminal region of PAX5 including its paired DBD, to the C-terminus of 
C20orf112, a protein of unknown function. We report that PAX5-C20S is a tetramer which 
interacts extraordinarily stably with chromatin as determined by fluorescence recovery after 
photobleaching (FRAP) in living cells. Tetramerization, stable chromatin-binding and DN-activity 
all require a putative five-turn amphipathic α-helix at the C-terminus of C20orf112, and does not 
require potential co-repressor binding peptides elsewhere in the sequence. In vitro, the monomeric 
PAX5 DBD and PAX5-C20S binds a PAX5-binding site with equal affinity when it is at the 
center of an oligonucleotide too short to bind to more than one PAX5 DBD. But PAX5-C20S 
binds the same sequence with tenfold higher affinity than the monomeric PAX5 DBD when it is in 
a long DNA molecule. We suggest that the increased affinity results from interactions of one or 
more of the additional DBDs with neighboring non-specific sites in a long DNA molecule, and 
that this can account for the increased stability of PAX5-C20S chromatin binding compared to wt 
PAX5, resulting in DN-activity by competition for binding to PAX5-target sites. Consistent with 
this model, the ALL-associated PAX5 fused to ETV6 or the multimerization domain of ETV6 
SAM results in stable chromatin binding and DN-activity. In addition, PAX5 DBD fused to 
Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, 
subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms
*Correspondence: Norihiko.Kawamata@cshs.org, berk@mbi.ucla.edu.
6These two authors equally contributed to this work as first authors.
7These two authors equally contributed to this work as senior authors.
HHS Public Access
Author manuscript
Oncogene. Author manuscript; available in PMC 2012 August 23.
Published in final edited form as:
Oncogene. 2012 February 23; 31(8): 966–977. doi:10.1038/onc.2011.291.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
artificial dimerization, trimerization, and tetramerization domains result in parallel increases in the 
stability of chromatin binding and DN-activity. Our studies suggest that oncogenic fusion proteins 
that retain the DBD of the transcription factor and the multimerization sequence of the partner 
protein can act in a DN fashion by multimerizing and binding avidly to gene targets preventing the 
normal transcription factor from binding and inducing expression of its target genes. Inhibition of 
this multimeriztion may provide a novel therapeutic approach for cancers with this or similar 
fusion proteins.
Keywords
PAX5 fusions; DNA binding; multimerization stable
Introduction
Gene fusions caused by chromosomal translocations contribute to the pathogenesis of many 
human neoplasms (Edwards, 2010). Most rearrangements are one of two types: 1) “promoter 
swapping,” which juxtaposes proto-oncogenes to abnormal transcriptional regulatory 
elements, leading to aberrant timing and/or expression level of a normal protein, or 2) 
fusions of two genes leading to expression of a chimeric fusion protein with abnormal 
function (Gasparini et al., 2007). Most oncogenic chimeric genes in the second class involve 
tyrosine kinases or transcription factors (TFs) (Mitelman et al., 2007). For oncogenic TF 
fusions, the resulting chimeric protein usually retains the TF DNA-binding domain (DBD) 
and results in either enhanced or reduced expression of target genes of the wild-type (wt) 
TF, promoting proliferation or blocking differentiation (O’Neil and Look, 2007). In many 
cases, oncogenic TF-fusions exert dominant-negative (DN)-activity over the wt TF 
expressed at a similar level from an unrearranged allele in the same cell (Pabst and Mueller, 
2007). In many of these examples, oncogenic TF-fusions may act as DNs because the fusion 
proteins contain repression domains that recruit co-repressors to target genes, inhibiting their 
expression despite co-binding of the wt protein to repeated binding sites in the same control 
regions (Grignani et al., 1998; Lin et al., 1998). However, in some cases, oncogenic DN-TFs 
are generated from fusions of DBDs to structural proteins (e.g. elastin (Bousquet et al., 
2007) or a myosin (Liu et al., 1993)) that have oligomerization domains, but no known 
repression domains. How oligomerization contributes to aberrant transcriptional activity is 
incompletely understood (So and Cleary, 2004).
PAX5 encodes a TF essential for B-cell differentiation that activates a number of B-cell 
specific genes and represses several genes specific for other hematopoietic lineages 
(Cobaleda et al., 2007). We and others have cloned a number of PAX5-fusion genes from 
acute lymphoblastic leukemia (ALL) cells (Table S1), including the two most commonly 
studied here, PAX5-C20orf112 (An et al., 2008; Kawamata et al., 2008) and PAX5-ETV6 
(Cazzaniga et al., 2001). In each case, the generated fusion proteins retain the N-terminal 
PAX5 DBD which is a paired domain that binds DNA as a monomer (Xu et al., 1995), and 
lack the C-terminal PAX5 activation domain (Dorfler and Busslinger, 1996). These fusion 
products are able to block the expression of PAX5 target genes and are associated with a 
block in B cell differentiation (Bousquet, M et al. 2006; Cobeleda C, 2007; Fazio et al, 
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2008; Kawamata et al, 2008). Here, we show that multimerization of the PAX5-DBD by the 
fusion partner is necessary and sufficient for DN-activity. Multimerization greatly increases 
the stability of the protein-chromatin interaction in living cells, probably through 
cooperative binding of the multimerized DBD to neighboring, non-specific low affinity 
DNA sites. The resulting high affinity binding of the fusion protein competes with wt PAX5 
binding to target genes. Inhibiting multimerization of the DBD interferes with stable 
chromatin binding and the resulting DN activity. Consequently, this would likely be a useful 
therapeutic strategy for either ALL with PAX5-fusions or other cancers with similar fusion 
proteins.
Results
Structural determinants of DN-activity
Two types of fusion genes associated with ALL involve PAX5 and C20orf112, PAX5-C20S 
resulting in an in-frame fusion of PAX5 exon 5 to C20orf112 exon 8 (Fig. 1A), and PAX5-
C20L generating an in-frame fusion of PAX5 exon 8 to C20orf112 exon 3 (An et al., 2008; 
Kawamata et al., 2008). We choose to focus on PAX5-C20S because it represents the 
smallest region of C20 still associated with development of ALL. Analysis of the C20orf112 
sequence in PAX5-C20S (Fig. 1B) revealed three regions that may contribute to DN-
activity: a putative binding motif for the CtBP co-repressor (Chinnadurai, 2002), a Ser-Thr-
Pro rich region, and the last 35 amino acids (aa) predicted to adopt an α-helical secondary 
structure (http://bioinf.cs.ucl.ac.uk/psipred/). The CtBP motif and the putative α-helical 
domain are highly conserved in C20orf112 orthologs from insects to humans (Fig. S1). To 
determine which regions of C20S are responsible for PAX5-C20S DN-activity over wt 
PAX5, we performed transient transfection assays with a luciferase reporter with three 
PAX5-binding sites derived from the murine CD19 promoter (Dorfler and Busslinger, 
1996). Experiments were performed with expression vectors for wt PAX5, PAX5-C20S, and 
derivatives of PAX5-C20S with yellow fluorescent protein (YFP) fused to their N-termini 
(Fig. 2A) in preparation for in vivo fluorescence studies described below. The YFP-N-
terminal fusion had little effect on either activation by PAX5-wt or the DN-activity of 
PAX5-C20S (compare Figs. 2A and S2). DN-activity was observed even though YFP-
PAX5-C20S was expressed at lower levels than YFP-PAX5-wt (Fig. S3). Deletion of the 
CtBP binding motif and the Ser-Thr-Pro rich regions of YFP-PAX5-C20S, but retention of 
the putative α-helical region (YFP-PAX5-C20-MD, Fig. 1B), did not diminish DN-activity 
(Fig. 2A). In contrast, deletion of the putative α-helical region, but retention of the CtBP 
binding motif and the Ser-Thr-Pro region (YFP-PAX5-C20ΔMD, Fig. 1B) nearly eliminated 
DN-activity (Fig. 2A), indicating that the proposed α-helical region of C20S is required for 
suppression of wt PAX5 activity. The slight reduction in luciferase observed with YFP-
PAX5-C20ΔMD was likely due to competition for binding to the reporter by the deleted 
protein that lacks an activation domain.
Results from chromatin immunoprecipitation (ChIP) assays using antibody specific for the 
C-terminus of wt PAX5 indicated that PAX5-C20S expression significantly reduced binding 
of wt PAX5 to the BLK PAX5-target gene in Nalm6 B-cell leukemia cells, even though the 
two proteins were expressed at similar levels (Kawamata et al., 2008). We speculated that 
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the C20orf112 C-terminal region might induce oligo- or multimerization of the PAX5 DBD, 
increasing PAX5-C20S DNA binding affinity by cooperative binding by two or more DBDs 
in the multimer to neighboring sites in chromosomal DNA. High affinity binding by the 
fusion might then compete for binding by wt PAX5 at equal concentrations. To test this 
hypothesis, we performed Fluorescence Recovery After Photobleaching (FRAP) 
experiments in living cells to measure the stability of chromatin-binding by wt PAX5 and 
PAX5-C20S in vivo. Fluorescence signals from most TF-fluorescent protein fusions recover 
quickly after photobleaching a region of the nucleus (t1/2 < 10 sec) (Phair et al., 2004). 
However, wt PAX5 displayed unusually stable binding with a t1/2 ~ 24 sec (Figs. 2B, 2C), 
consistent with a recent report that several members of the PAX family TFs in general 
exhibit slow recovery times (Elvenes et al., 2010). Remarkably, the leukemogenic PAX5-
C20S fusion exhibited extremely slow recovery in the FRAP assay (estimated t1/2 ~200 sec), 
while YFP-labeled C20orf112 displayed a t1/2 ~ 3 sec (Figs. 2B and 2C).
To examine which regions of the fusion protein are responsible for its unusually slow 
nuclear mobility, we performed FRAP assays with several deletions of PAX5-C20S fused to 
YFP. Deletion of the PAX5-DBD (Fig. 1A) showed that it is required for stable binding 
(Fig. 2D), suggesting that low PAX5-C20S nuclear mobility requires binding to DNA in 
chromatin. The DBD was also required for DN-activity in the reporter assay (Fig. S4A). All 
of these YFP-labeled constructs localized to the nucleus (Fig. S4B). FRAP assays with YFP-
PAX5-C20ΔMD and YFP-PAX5-C20MD (Fig. 2E) showed that the putative α-helical 
region at the C-terminus is required and sufficient for the decreased mobility of PAX5-
C20S; decreased mobility does not require either the CtBP binding motif or the Ser-Thr-Pro 
rich region. FRAP was also performed with YFP fused to the region of PAX5 in PAX5-
C20S encoded by exons 1–5 (“PAX5-Exon 5” (Fig. 1A) which gave a t½ ≈ 4 sec (Fig. 2D). 
Consequently, the region of PAX5 C-terminal to the portion in PAX5-C20S is required for 
the slow nuclear mobility of wt PAX5. However, this cannot contribute to the stability of 
PAX5-C20S chromatin-binding since it is absent from the fusion protein. Also, a potential 
octapeptide Groucho repression motif in exon 5 of PAX5 (“O” in Fig. 1A), does not 
contribute significantly to the DN-activity of PAX5-C20S, since mutation Y179E in PAX5 
disrupts interactions with the Groucho proteins (Berhard et al., 2000) and had no effect on 
the stable chromatin binding of PAX5-C20S and only a minor effect on the DN-activity of 
either PAX5-C20S or the PAX5-p53tetra fusion (Figs. S5A, B). Thus, the putative C-
terminal α-helical region of PAX5-C20S greatly increases the stability of chromatin-binding 
and is required for DN-activity.
We also examined the product of the PAX5-ETV6 fusion gene, the most frequently reported 
PAX5-fusion in ALL (Table S1). The portion of ETV6 fused to the N-terminus of PAX5 
contains a SAM domain whose crystal structure reveals a head-to-tail polymer (Kim et al., 
2001) that we speculated might result in stable chromatin binding as we observed for PAX5-
C20S. Indeed, both YFP fused to PAX5-ETV6 and to the N-terminal region of PAX5 fused 
to the SAM domain alone (YFP-PAX5-SAM) exhibited stable chromatin binding 
comparable to that of YFP-PAX5-C20S (estimated t1/2 ≈200 sec) (Fig. S5C). Reporter gene 
assays showed that the SAM domain alone was sufficient to generate a potent DN-activity 
equivalent to that of PAX5-ETV6 (Fig. S5D).
Kawamata et al. Page 4
Oncogene. Author manuscript; available in PMC 2012 August 23.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
PAX5-C20S has a C-terminal homo-multimerization domain
A helical-wheel projection (Fig. 3A) of the C20S C-terminal sequence revealed 4–3 
hydrophobic heptad repeats, consistent with an amphipathic helix. To determine if the 
predicted amphipathic α-helix is involved in PAX5-C20S oligomerization, we expressed 
separate fusions of YFP and CFP to C20orf112 residues 391–436 (“C20HL”) in transfected 
293T cells and performed fluorescence resonance energy transfer (FRET) assays by flow 
cytometry, a sensitive method for detecting the interaction of two proteins in vivo in 
thousands of individual cells (Siegel et al., 2000). YFP-C20HL and CFP-C20HL showed 
strong FRET signals, similar to the positive control of a CFP-YFP tandem fusion (Fig. 3B). 
FRET was also observed using YFP-PAX5-C20S and CFP-PAX5-C20S (Fig. 3B), 
suggesting that PAX5-C20S fusion proteins associate through an α-helical region at their C-
termini.
To confirm oligomerization of PAX5-C20S, YFP-fusion proteins in nuclear extract (Dignam 
et al., 1983) from the same cells used for the FRAP studies were subjected to gel filtration 
chromatography (Fig. 3C). YFP and YFP-PAX5-wt eluted as predicted for monomeric 
proteins. However, YFP-PAX5-C20S eluted much earlier than YFP-PAX5-wt, consistent 
with formation of a multimer. Purified PAX5-C20S-His6 (31.2 kD) expressed in E. coli 
eluted just after the peak of Aldolase (158 kD), consistent with a tetramer (Fig. 3D). In 
contrast, when PAX5-Exon5-His6, containing only the portion of PAX5 included in PAX5-
C20S (25.4 kD), was similarly expressed in and purified from E. coli, it eluted as expected 
for a monomer (Fig. 3D). Interestingly, in gel filtration the YFP-PAX5-SAM fusion eluted 
in multiple fractions including the void volume (>2 MDa) indicating that it can form 
polymeric species from dimer to high-order polymers (data not shown), consistent with the 
crystal structure of the SAM domain.
We also co-expressed PAX5-C20S with either YFP-PAX5-C20S or YFP-PAX5-wt in 293T 
cells and performed co-immunoprecipitation assays with anti-YFP antibody. As expected 
from the results indicating that PAX5-C20S forms a tetramer, PAX5-C20S co-
immunoprecipitated with YFP-PAX5-C20S. However, importantly, PAX5-C20S failed to 
co-immunoprecipitate with YFP-PAX5-wt (Fig. 3D), indicating that while PAX5-C20S 
forms homo-multimers, it does not interact with monomeric wt PAX5 expressed in the same 
cell. Thus, the DN-activity of PAX5-C20S does not result from the formation of mixed 
multimers between wt PAX5 and the oncogenic, multimeric fusion protein.
Multimerization of PAX5 and DN-activity
Mutation of leucine 421 (Fig. 3A) to proline near the middle of the proposed C-terminal 
amphipathic helix of C20orf112 is predicted to greatly reduce the propensity of this 
sequence to form interacting alpha helices [using Marcoil (Delorenzi and Speed, 2002), 
Paircoil2 (McDonnell et al., 2006), and COILS/PCOILS (Gruber et al., 2005) programs]. 
Gel filtration showed that this mutation converts YFP-PAX5-C20S to a monomer (Fig. 3C). 
Consistent with the model that stable chromatin binding and DN-activity of PAX5-C20S 
results from multivalent interactions between several DBDs in a PAX5-C20S multimer and 
several sites in DNA, the L421P mutation caused both a substantial decrease in FRAP t1/2 
(Fig. 4A) and a prominent loss of DN-activity (Fig. 4B).
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To test the hypothesis further, we fused the N-terminal region of PAX5 to previously 
characterized protein oligomerization domains known to form either a dimer, trimer, or 
tetramer (Fig. 5A). The p53 tetramerization domain (p53tetra, aa 305–360) has been studied 
extensively and shown to behave as either a monomer or dimer with single point mutants 
L344P and L344R, respectively (Davison et al., 2001). In the exhaustively studied p53 
protein, the tetramerization domain is not known to function directly in transcriptional 
repression by interacting with co-repressors. The foldon domain is a trimerization module 
from the C-terminal 27 aa of phage T4 fibritin (Letarov et al., 1999). The fusion proteins 
expressed in p53-minus H1299 cells eluted from a gel filtration column according to their 
predicted oligomeric states (Fig. 5B). The peaks of YFP-PAX5-C20S and YFP-PAX5-
p53tetra eluted in the same fractions (Figs. 3C and 5B), consistent with the conclusion that 
the C20orf112 C-terminal region is a tetramerization domain based on gel filtration of 
PAX5-C20S-His6 expressed in E. coli (Fig. 3D). Importantly, FRAP assays of these 
artificial multimers showed increasing stability of protein-chromatin interactions in vivo in 
parallel with the increasing number of PAX5-DBDs in the multimer (Fig. 5C). The t1/2 
increased by ~2-3-fold as the oligomeric state of the fusion increased successively from 
monomer to dimer, etc. Significantly, luciferase reporter assays showed that DN-activity 
increased in parallel with the number of monomers in the multimer and the resulting 
increase in stability of chromatin binding (Figs. 5D). Fusion of the p53 tetramerization 
domain generated DN-activity comparable to that of PAX5-C20S. Further, to confirm if this 
artificial fusion PAX5 which tetramerizes via the p53 tetramerization domain suppressed 
PAX5 downstream target genes, we transfected either YFP-PAX5-p53tetra, YFP-PAX5-
C20s, or YFP constructs into Daudi cells (Burkit B-cell lymphoma cell line). YFP-positive 
cells were sorted and expression levels of PAX5 downstream target genes (Schebesta A et 
al. 2007) were examined by semi-quantitative RT-PCR. Expression levels of two major 
PAX5 downstream target genes (Blk and BCAR3) (Schebesta A et al. 2007) were 
suppressed by YFP-PAX5-p53tetra as strongly as by YFP-PAX5-C20s (Fig. 5E).
PAX5-C20S binds DNA in vitro with ten-fold higher affinity than a monomeric PAX5 DBD
The unusual stability of chromatin binding by PAX5-C20S and PAX5-ETV6 might be 
accounted for by multivalency, i.e. the binding of multiple DBDs in the same stable 
multimer to nearby specific and non-specific sites in chromosomal DNA. Since KDs of TF 
DBDs for non-specific sites are often in the 10−4 to −6 M range, the affinity of such a 
multimer would increase as the number of DNA-binding domains in the multimer increases. 
Such an effect would be missed in the earlier reported in vitro assays of DNA-binding that 
did not show a difference in affinity between wt PAX5 and PAX5-C20S (Kawamata et al., 
2008) because the short oligonucleotide probe used could be bound by only a single DNA-
binding domain. To test this possibility, we performed in vitro DNA binding assays 
(EMSAs) using recombinant PAX5 proteins purified from E. coli and long unlabeled DNA 
molecules in competition experiments with a short 32P-labeled oligonucleotide probe 
containing a single PAX5 binding site. We were not able to express full-length wt PAX5 at a 
high level in E. coli, and consequently compared PAX5-C20S to the portion of PAX5 that is 
fused to C20orf112 in PAX5-C20S (Fig. 1A, PAX5-Exon5). As expected for a tetramer, 
PAX5-C20S generated a slower mobility EMSA band than the monomeric PAX5 paired 
DNA-binding domain in PAX5-Exon5 (Fig. 6). The PAX5-C20S DNA-protein complexes 
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resolved into two bands, probably due to binding of one or two oligonucleotide probes to 
separate DBDs in the tetramer. Failure to observe three or four bands may indicate that 
steric restraints restrict binding to more than two oligonucleotides probes.
To assay differences in binding affinity to short and long DNA molecules, we added 
increasing amounts of cold competitor DNAs to a labeled 46 bp probe before the addition of 
protein. The 46 bp labeled probe is bound by a single PAX5 paired DBD that protects 28 bp 
at the center of the probe from DNase I digestion (Czerny et al., 1993; Xu et al., 1995). 
When the unlabeled probe was added as competitor, it competed equally the binding of the 
labeled probe to the PAX5-Exon 5 monomer and the PAX5-C20S tetramer (Fig. 6A). 
However, significantly, when a 5.15 kb plasmid with a single PAX5 binding site was used 
as competitor, competition to 50% probe binding was observed at one-tenth the competitor 
concentration for PAX5-C20S compared to PAX5-Exon5 (Fig. 6B), indicating that PAX5-
C20S has ten-fold higher affinity for a PAX5 site in a long DNA molecule, like cellular 
DNA, than a monomeric PAX5-DBD. Since the plasmid contains a single specific PAX5-
binding site, the increased affinity probably results from interactions of one or more of the 
additional DBDs in the tetramer with non-specific sites in the long DNA. The plasmid 
competed probe binding to the monomeric PAX5-Exon5 at a lower concentration than the 
cold 46 bp probe (50% probe binding at 1 versus 9 nM) because in the binding reactions 
with the plasmid, competition also occurs from the high number of low affinity non-specific 
sites in the plasmid—every bp of the 5.15 kb plasmid constitutes the first bp of another non-
specific site.
A plasmid with two PAX5-binding sites separated by 2 kb competed for binding to the 
monomeric PAX5-Exon5 at about one-half the concentration of the plasmid with a single 
PAX5 binding site (Fig. 6C) as expected, since the concentration of specific sites is two 
times higher for the same concentration of plasmid. The increased affinity of PAX5-C20S 
for the plasmid with two PAX5 sites remained 10-fold higher than for monomeric PAX5-
Exon5. Similar results were observed for the luciferase reporter plasmid with three high 
affinity PAX5 binding sites separated by 49 bp between the centers of the sites (data not 
shown). These results support the conclusion that the increased affinity of PAX5-C20S 
results from interactions of one or more of the three extra DBDs in the PAX5-C20S tetramer 
with a neighboring non-specific site or sites. Otherwise, one would have expected a much 
greater increase in affinity for plasmids with two and three specific sites compared to the 
plasmid with a single specific site.
Inhibition of PAX5-C20S DN-activity by expression of the C20S tetramerization domain
Our data support the model that tetramerization of the PAX5 DBD via the C-terminal region 
of C20S causes high affinity binding of the oncogenic TF-fusion to its cognate DNA binding 
sites, competing for binding by wt PAX5. This model suggests that co-expression of the 
C20orf112 tetramerization domain not fused to a PAX5-DBD would disrupt tetramerization 
of the DBD via hetero-oligomerization, and consequently interfere with PAX5-C20S DN-
activity. To test this, we co-expressed PAX5-ΔDBD-C20S with PAX5-C20S, using a four-
fold excess of the PAX5-ΔDBD-C20S vector. DN activity was nearly eliminated as 
measured by reporter assay (Fig. 7A). A similar result has been reported for disruption of 
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both the tetramerization and transforming activity of RUNX1-ETO by expression of an ETO 
multimerization domain (Wichmann et al., 2007). FRAP assays with CFP-PAX5-ΔDBD-
C20S in the same cells as YFP-PAX5-C20S confirmed that the stability of YFP-PAX5-
C20S association with chromatin was decreased considerably, although it is unclear why 
recovery of fluorescence plateaued at ~80% (Fig. 7B). Similarly, the rapid nuclear mobility 
of PAX5-ΔDBD-C20S (t1/2 ~ 1 s) was decreased substantially by co-expression of an equal 
amount of CFP-PAX5-C20S (t1/2 ~ 25 s, Fig. 7C). The specificity of this effect was 
demonstrated in experiments with YFP-PAX5-p53tetra whose DN-activity was not affected 
by PAX5-ΔDBD-C20S (Fig. 7D). These data confirm that multimerization of the PAX5 
DBD causes stable chromatin binding, and demonstrate that disruption of the 
multimerization interface is sufficient to reverse PAX5-C20S DN-activity.
Discussion
The requirement for induced oligomerization of oncogenic TF fusions for DN-activity was 
originally identified in studies of RARα and RUNX1 fusions (Lin and Evans, 2000; Minucci 
et al., 2000). Some of the oligomerization domains fused to the RARα DBD contribute to 
DN activity by enhancing recruitment of co-repressors, such as SMRT, binding partner 
RXR, and by relaxing the DNA binding specificity compared to wt RARα/RXR (Kamashev 
et al., 2004; Lin and Evans, 2000; Martens et al., 2010; Minucci et al., 2000; Zhou et al., 
2006). Here, we present evidence that for DN PAX5-fusions, oligomerization of the DNA 
binding domain (DBD) alone is sufficient to suppress activation by wt PAX5, and 
consequently, to contribute to leukemogenesis, without invoking recruitment of co-
repressors. We propose that PAX5-DBD oligomerization to a tetramer (PAX5-C20S, PAX5-
p53tetra) or higher order multimer (PAX5-ETV6 SAM domain) results in an ~10-fold 
increase in affinity for PAX5 binding sites through interactions of the additional DBDs in 
the oligomer with neighboring non-specific sites in DNA, competing with wt PAX5 to target 
genes.
Gel filtration chromatography of recombinant PAX5-C20S purified from E. coli indicated 
that the fusion protein forms a stable tetramer. Further evidence that PAX5-C20S is a 
tetramer comes from the observation that YFP-PAX5-C20S co-eluted from the gel filtration 
column with a YFP-fusion of the same N-terminal region of PAX5 to the well-characterized 
p53 tetramerization domain. This led to a great increase in the stability of chromatin-binding 
by the fusion proteins compared to wt PAX5 as determined by FRAP assays in living cells. 
A similar finding was noted when the DNB region of PAX5 was fused to the multermization 
region of p53.
In vitro DNA-binding assays revealed that PAX5-C20S has ~10-fold higher affinity for a 
PAX5-binding site in plasmid DNA compared to the monomeric PAX5 DBD. 
Consequently, the increased stability of chromatin binding by PAX5-C20S may be 
accounted for largely by the increase in DNA-binding affinity of the tetramer compared to 
the monomer. This increased DNA-binding affinity probably involves cooperative binding 
of more than one DBD in the PAX5-C20S tetramer to DNA, since no difference in affinity 
was observed for an oligonucleotide containing the same high affinity PAX5-binding site, 
but which was too short to interact with more than one DBD. Further, the increase in affinity 
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is probably due to interactions between DNA-binding domains in the multimer and 
neighboring non-specific sites in a long DNA molecule since it was observed with a plasmid 
containing a single high affinity consensus PAX5-binding site.
In hypothesis confirming studies, we noted no change in the stability of chromatin-binding 
assayed by FRAP by mutation of potential co-repressor binding sites in the PAX5-C20S 
sequence. But, a single leucine to proline mutation (L421P) in the predicted amphipathic α-
helical tetramerization domain inhibited YFP-PAX5-C20S stable multimerization and 
greatly decreased the stability of binding to chromatin. Strikingly, when the PAX5 N-
terminal region was fused to p53 domains or fibritin that generated either a dimer, a trimer, 
or a tetramer, the stability of chromatin binding and the DN-activity of the fusion protein 
increased in parallel. Consequently, the increased stability of chromatin-binding by PAX5-
C20S compared to wt PAX5 seems best explained by the increased DNA-binding affinity of 
the tetramer compared to the monomer, without invoking binding by a co-repressor. Our 
experiments with another PAX5 fusion (PAX5-ETV6) suggest that it too behaves in as a DN 
in a similar fashion.
Earlier, we observed by chromatin immunoprecipitation that PAX5-C20S expressed at a 
similar concentration to endogenous wt PAX5 in cultured B-cells, significantly reduced 
binding of wt PAX5 to its cognate binding site in the BLK gene (Kawamata et al., 2008). 
The results discussed above strongly suggest that this decrease is due to competition for 
binding to the same site by PAX5-C20S, which binds to a PAX5-site in chromosomal DNA 
with ~10-fold higher affinity than the monomeric PAX5 DBD in wt PAX5.
Earlier FRAP studies of other fusion proteins associated with hematopoietic malignancies 
have been reported including RARα fusions to either PML, PLZF, NPM, NuMA, or 
STAT5b in acute promyelocytic leukemia (APL) (Dong et al., 2004; Huang et al., 2008), 
RUNX1 fusions to ETO and MTG16 in acute myeloid leukemia (AML) (Qiu et al., 2006), 
and, recently, a PAX5-PML fusion (Qiu et al., 2010). In most cases, only modest decreases 
in nuclear mobility compared to the wt TF were observed. Only in the cases of PML-RARα 
and PAX5-PML was the decrease in nuclear mobility as dramatic as observed here for 
PAX5-C20S and PAX5-ETV6. Moreover, as for PAX5-C20S, the unusually slow nuclear 
mobility of these fusions to PML is dependent on an amphipathic helical domain contributed 
by the PML fusion partner (Huang et al., 2008; Qiu et al., 2010) that oligomerizes into a 
tetramer (Antolini et al., 2003). In other cases of ALL, PAX5 is fused to other partner genes 
that provide multimerization domains, including FOXP1 and the extracellular protein Elastin 
(Strefford et al., 2009). Many of the other PAX5-fusion partners associated with ALL 
(ZNF521, JAK2, BRD1, DACH1, DACH2, GOLGA6, and KIF3B) contain putative, as yet 
uncharacterized oligomerization domains. Our findings are probably applicable to many 
other oncogenic fusions containing the DBD of a transcription factor and a multimerization 
domain of the other partner. Since disruption of PAX5-DBD multimerization nearly 
eliminated the DN-activity of PAX5-C20S, pharmacologic interference with 
multimerization of the PAX5-fusion proteins, or indeed any similar oncogenic fusion might 
be a novel therapeutic approach.
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Experimental Procedures
(Detailed procedures in Supplementary Information)
Cell lines and transfection
293T and H1299 (p53−/−) cells were transfected with Effectene (Qiagen) or Lipofectamine 
2000 (Invitrogen) according to the manufacturers’ protocols. Burkitt B-cell line, Daudi, was 
maintained in RPMI1640 media with 10% fetal calf serum. Six microgram of YFP, YFP-
PAX5-p53tetra, or YFP-PAX5-C20S constructs were transfected into 3 × 106 Daudi cells 
using Amaxa Nucleofector (Solution L and Condition A20) according to the manufacturer’s 
recommendation (Lonza, Basel, Switzerland).
Vectors
Wt PAX5 cDNA was cloned into the pMSCV vector (Clontech). All YFP or CFP containing 
constructs were cloned into pcDNA3.1 (Invitrogen).
Luciferase reporter assays
Three PAX5 recognition sites derived from the murine CD19 promoter were placed in front 
of firefly luciferase in pGL2-basic (Promega) (Dorfler and Busslinger, 1996) with pRenilla-
luciferase-SV40 (Promega) used as a transfection efficiency control. Luciferase activities 
were measured using Promega Dual Luciferase reporter assay kit.
FRAP
In these experiments, a region of fluorescent proteins within the nucleus is irreversibly 
bleached by a short, intense laser pulse, and recovery of fluorescence in the bleached region 
is monitored over time. After photobleaching, bleached molecules dissociate from their 
binding sites and are replaced by non-bleached fluorescent proteins that diffuse from outside 
the bleached region. Proteins that are highly mobile generate fast recovery curves while 
proteins tightly bound to anchored sites in the nucleus, such as chromosomes, recover 
slowly (Sprague and McNally, 2005). Live 293T or H1299 cells were imaged 24 h post-
transfection (800 ng vector per dish) with a Leica TCS SP2 AOBS single photon confocal 
microscope with the stage and 63×1.4-numerical-aperture oil immersion objective placed in 
an enclosed chamber pre-equilibrated to 37°C with continuous flow of 5% CO2 over the 
microscope stage.
FRET
293T were transfected using Effectene. Living cells were suspended in PBS and assays 
performed on FACStar as described (Siegel et al., 2000) with 436 nm laser excitation and 
emission detected with 480 nm (x axis) and 535 nm (y axis) filters.
EMSAs
Electrophoretic mobility shift assays were performed with a 46-bp probe containing one 
PAX5 binding site as described (Czerny et al., 1993) using recombinant proteins purified by 
Ni+2 affinity and gel filtration chromatography.
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Cell sorting and semi-quantitative RT-PCR
YFP positive transfected Daudi cells were sorted by FACStar Cell Sorter (Becton, 
Dickinson and company, Franklin Lakes, NJ). Total RNA was extracted and complementary 
DNA was genereated using SuperScript® III One-Step RT-PCR system (Invitrogen, 
Carlsbad, CA). Expression levels of beta actin in each samples were examined by 25 cycles 
of PCR reaction; expression levels of two PAX5 downstream target genes, Blk and BCAR3 
genes, were also examined by 30 and 32 cycles of PCR amplification, respectively. Ten 
microliter of each of the PCR products were run in 2% gel. PCR products were 
photographed and density of each PCR band was measured by NIH image software (http://
rsb.info.nih.gov/nih-image/index.html).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Structural determinants of PAX5-C20orf112 oncogenic fusion protein
(A) Domains of PAX5 (Cobaleda et al., 2007), C20orf112, PAX5-C20S, PAX5ΔDBD-C20S 
with the paired DBD deleted, and PAX5-Exon5 (encoded by PAX5 exons 1–5, the portion of 
PAX5 in PAX5-C20S). The PAX5 DNA-binding domain [PD (DBD)], an octapeptide motif 
bound by Groucho-family co-repressors (O), and a nuclear localization sequence (N) are 
included in PAX5-C20S while its partial homeodomain (HD), activation domain (TAD), and 
inhibitory domain (ID) are not. Black arrows indicate points of fusion. (B) Analysis of 
C20orf112 sequence in PAX5-C20S reveals three regions that may contribute to DN 
activity: a CtBP binding motif (P×DLS×K), a serine-threonine-proline (Ser-Thr-Pro)-rich 
region, and a putative α-helical region. Constructs that contain bracketed parts of C20S are 
YFP-PAX5-C20-MD that fuses only the α-helical region, and YFP-PAX5-C20ΔMD that 
fuses only the P×DLS×K motif and the Ser-Thr-Pro rich region.
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Figure 2. PAX5-C20S suppresses wt PAX5 activity and causes extremely slow nuclear mobility 
in living cells
(A) A YFP-PAX5-wt vector and the luciferase reporter were either transfected or co-
transfected with vectors for YFP-PAX5-C20S, YFP-PAX5-C20-MD, or YFP-PAX5-
C20ΔMD and luciferase assayed (RLU). (B) Fluorescence micrographs from FRAP assays 
in 293T cells. Red circled areas were photobleached regions, and fluorescence signal in each 
area was sequentially measured. FRAP assays of (C) YFP-PAX5-C20S (black circles, N=4, 
t1/2 ~ 200 sec), YFP-C20orf112 (purple circles, N=4, t1/2 ~ 3 s) and YFP-PAX5-wt (red 
circles, N=7, t1/2 ~ 24 s) in 293T cells, (D) YFP-PAX5-ΔDBD-C20S (orange circles, N=3, 
t1/2 ~ 1 s), YFP-PAX5-C20S (black circles, N=4, t1/2 ~ 200 s), and YFP-PAX5-Exon5 (blue 
circles, N=3, t1/2 ~ 4 s) in 293T cells, (E) YFP-PAX5-C20ΔMD (gold squares, N=6, t1/2 ~ 1 
s), YFP-PAX5-C20-MD (pink diamonds, N= 7, t1/2 ~200 s), and YFP-PAX5-C20S (black 
circles, N=5, t1/2 ~200 s) in H1299 cells. Error bars here and in subsequent FRAP assays 
represent standard error of the mean.
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Figure 3. α-helical region of C20S mediates multimerization
(A) Helical wheel projection of the predicted α-helix (aa 402–436). Heptad positions are 
labeled by letters ‘a’ through ‘g’ in the wheels. Hydrophobic residues occur at positions ‘c’ 
and ‘f’. The leucine at position 421 mutated to proline is boxed in projection and underlined 
in the sequence
(B) Results of FRET assays. CFP or YFP fusion proteins were transiently expressed in 293T 
cells, and FRET signals were detected by flow cytometry. Cells were excited with a 436 nm 
laser, and emission signals were measured at 480 nm (x axis) and 535 nm (y axis). When 
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FRET occurs, yellow signals (535 nm, y axis) increase. Signals in the triangular areas 
indicate cells with FRET signals. In a negative control (i), independent CFP and YFP 
proteins were co-expressed and produced no significant FRET signal (rare signals in the 
triangular area). A YFP-CFP fusion protein was expressed and used as a positive control (ii), 
showing that most cells exhibited strong FRET signals. (iii) Expression of YFP-C20HL and 
CFP-C20HL produced FRET signals comparable to the YFP-CFP fusion positive control. 
(iv) Expression of YFP-PAX5-C20S and CFP-PAX5-C20S produced a FRET signal in most 
cells of lower magnitude because of the greater distance between the YFP and CFP.
(C) Gel filtration analysis of YFP, YFP-PAX5, YFP-PAX5-C20S, YFP-PAX5-C20-ΔMD, 
and YFP-PAX5-C20S-L421P. Proteins were expressed in H1299 cells, extracted from 
nuclei, and fractionated by gel filtration. Column fractions were subjected to 
immunoblotting with anti-YFP antibody. Fraction numbers are indicated above panel with 
protein standards eluted at specific volumes as indicated by arrows.
(D) Gel filtration of PAX5-C20S-His6 and PAX5-Exon5-His6 expressed in and purified 
from E. coli.
(E) Co-immunoprecipitation assays. (left panel: Input) PAX5-C20S was co-expressed with 
either YFP-PAX5-C20S or YFP-PAX5-wt in 293T cells. Expression of each protein was 
confirmed by immunoblotting cell extracts with YFP-specific antibody (top panel) or 
antibody specific for the C20 C-terminus (bottom panel). (Right panel) extracts were 
immunoprecipitated using YFP-antibody and immunoblotted as for the input panels.
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Figure 4. Disruption of C20S multimerization abrogates suppression of PAX5 activity and stable 
chromatin binding
(A) FRAP assay comparing YFP-PAX5-C20-ΔMD (gold squares, N=5, t1/2 ~ 2 s), YFP-
PAX5-C20S-L421P (gray diamonds, N=5, t1/2 ~ 5 s), and YFP-PAX5-C20S (black circles, 
N=4, t1/2 ~ 200 s) at 24 h post-transfection in H1299 cells.
(B) YFP-PAX5-wt and the luciferase reporter were co-transfected alone, or with YFP-
PAX5-C20S, YFP-PAX5-C20-MD, YFP-PAX5-C20-ΔMD, and YFP-PAX5-C20S-L421P, 
and luciferase activity assayed.
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Figure 5. Multimerization of PAX5 fusions mediates suppression of wt PAX5 activity and stable 
chromatin binding
(A) Structure of PAX5-fusions: PAX5-p53tetra-L344P (monomer), PAX5-p53tetra-L344R 
(dimer), PAX5-Foldon (trimer), and PAX5-p53tetra (tetramer) domain. The fusions include 
the same N-terminal region of PAX5 in PAX5-C20S fused to the oligomerization domain of 
the fusion partner, p53 (aa 305–360) and foldon (aa 458–484). PAX5-SAM fusion contains 
the same region of PAX5 fused to the ETV6 SAM multimerization domain.
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(B) Gel filtration analysis of YFP-PAX5-fusions. Proteins were expressed in H1299 cells, 
extracted, fractionated by gel filtration, and detected by immunoblotting with anti-YFP 
antibody.
(C) FRAP assays with YFP-PAX5 fusions in H1299 cells. FRAP recovery curves of YFP-
PAX5-L344P (red diamonds, N= 3, t1/2 ~ 3 s), YFP-PAX5-L344R (green diamonds, N=3, 
t1/2 ~ 14 s), YFP-PAX5-Foldon (blue diamonds, N=5, t1/2 ~ 50 s), and YFP-PAX5-
wtp53tetra (black diamonds, N=5, t1/2 ~ 200 s) show that increasing multimerization of the 
PAX5 DNA binding domain results in increasing stability of chromatin association.
(D) YFP-PAX5wt and reporter gene were co-transfected either alone or with YFP-PAX5-
L344P, YFP-PAX5-L344R, YFP-PAX5-Foldon, YFP-PAX5-wtp53tetra, or YFP-PAX5-
C20S in p53-minus H1299 cells. Increasing multimerization of the PAX5 DNA binding 
domain caused increasing suppression of YFP-PAX5wt activity.
(E) Semi-quantitative RT-PCR. Expression levels of two major PAX5 downstream target 
genes, Blk and BCAR3, as well as beta-actin (internal control) were examined by semi-
quantitative RT-PCR. Products were amplified from cDNA of Burkit B-cell line, Daudi 
transfected with either YFP, YFP-PAX5-p53tetra, or YFP-PAX5-C20S (PCR cycle for 
Beta-actin: 25; PCR cycles for Blk: 30; PCR cycles for BCAR3: 33). Ten microliter of each 
PCR product was run in 2% agarose gel. Relative semi-quantitative levels of each PCR 
product to beta-actin PCR product are graphed uner each panel of PCR bands; levels of PCR 
products from Daudi cells transfected with YFP alone were regarded as 1.
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Figure 6. PAX5-C20S tetramer has greater affinity in vitro for a PAX5 site in a long DNA 
molecule than monomeric PAX5-Exon5
(A) EMSA using a 46 bp 32P-labeled high affinity PAX5 binding site (PAX5BS) derived 
from the CD19 promoter (Czerny et al., 1993). Increasing amounts of unlabeled 46-bp 
PAX5BS (0.1, 0.4, 1.6, 6.4, 26, 100, 400 nM) were added before addition of protein to the 
binding reaction. The fraction of labeled 46-bp PAX5BS probe bound by protein (PAX5-
Exon5 or PAX5-C20S) was calculated and plotted to the right relative to the amount bound 
without competitor. Results from two independent assays are indicated by the green squares 
and blue diamond symbols for PAX5-Exon5 and the red triangles and black circles for 
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PAX5-C20. (B, C) Performed as in (A) except the unlabeled competitor DNA (0.1, 0.3, 1.0, 
3, 10, 30, 100 nM) was a 5.15 kb plasmid with one or two copies (separated by 2 kb) of the 
46 bp PAX5BS cloned into it. The data were fit by the variable slope sigmoid equation (see 
Experimental Procedures, Supplemental Materials).
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Figure 7. The C20S tetramerization domain suppresses the dominant negative activity of PAX5-
C20S
(A) Vectors for PAX5-wt, PAX5-C20S, and PAX5-C20SΔDBD and the luciferase reporter 
were transfected into 293T cells as indicated and luciferase assayed after 24 h. FRAP assays 
for (B) YFP-PAX5-ΔDBD-C20S (orange circles, N=3, t1/2 ~ 1 s), YFP-PAX5-C20S co-
expressed with four-fold more CFP-PAX5-ΔDBD-C20S (YFP FRAP gray diamonds, N=7, 
t1/2 ~ 4 s), and YFP-PAX5-C20S (black circles, N=4, t1/2 ~ 200 s), and for (C) YFP-PAX5-
ΔDBD-C20S (orange circles, N=3, t1/2 ~ 1 s), YFP-PAX5-ΔDBD-C20S and an equal 
amount of CFP-PAX5-C20S (gray circles, N=8, t1/2 ~ 25 s), and YFP-PAX5-C20S (black 
circles, N=4, t1/2 ~ 200 s). (D) PAX5-wtp53tetra was expressed with wt PAX5 and PAX5 
reporter gene either with or without PAX5-C20SΔDBD and luciferase assayed.
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